everyone. you, Thank afternoon good Jim and
revenue XXXX, and offerings solidify running in areas our position continued advancements investing we the both establish of of synbio in leadership and product very are the all business, NGS well growth will sources and of space. in technological additional and that our Over across course
that year, verticals. we and, we series am pleased the of of these cases, report our exceeding of outlined to I objectives in goals. for some At each the a are beginning fiscal ambitious meeting
NGS customers we the fiscal compared quarters $XX.X Overall, to reported this of full have fiscal quarter. in customers shipped three the we And for first the of X,XXX revenues year. in and million synbio year XXXX to XXX
was a revenue topline accomplishment. quarter second we Indeed, sequentially fiscal million. a quarter, accounting $X our our over revenues While for the significant flat had single customer accrued almost last
liquid order, increased biopsy-related large by sequentially. revenues million this have $X Excluding close would our to
customers we For synbio, revenue we growth X,XXX have to and continue shipped now this year in see almost to segment. fiscal this
move San into the our facility a During in production manufacturing the prepared quarter, back-end gene third new of South we Francisco.
We are production of July orders that pleased and the without July Xst that to any weeks came move the interruptions in the smoothly period minimum delays July for first only through during XXth. report with from gene went in the
long tail increased customer fueled reaching In is We indicating QX, year-over-year, at reaching while year-over-year XX% of we're X.Xx customers about market. size trajectory, e-commerce the the orders the of that platform market. believe we're our of a the average by beginning the by this order number in smaller the decreased while
Revenue this million from Twist. of we need year quantities for them $X.X reflecting quarter continued or from the continue DNA large meet was and expect obligations their Ginkgo to third contractual $X exceed million Ginkgo's for of to
the Arzeda, workflow cycle. During design build and that the respective a we platforms the Labcyte, TeselaGen with accelerates event an create showcasing the of to co-hosted individual quarter, integration test
field value an there The biology. April, in the detailed that growing synthetic was of of And Economist article in insightful the
technologies out synbio new integrating convergence is growing in the article, research. What in described different to the technology a of is to readiness and of of market and embrace a spur the playing exciting benefits
from capabilities an play with and proprietary our synbio writing of technology. in we DNA our produce investment to the that integral part continue the We products
which a Historically, on bases to the make XXX our is longest or innovation, in long been difficult oligos up testament length, our introduction it to to believe has XXX longer oligo to in bases oligos in nucleotides oligo than due chemical we As industry. offering the announced reaction we Monday, of continuous the commercial efficiencies.
but identified way have advantage, our a a make can where this to store our data strand. at longer useful drug bases data oligos We oligos DNA oligo also a in only a are believe provides longer error rate. storage, us more and in where record very low discovery product, of proprietary per pieces competitive XXX We development in not digital
well useful and be synergistic for we very as oligos protein guides. synthesis to directly effects addition, of believe two engineering. bases enabled RNAs cooperative editing CRISPR multiple in of a gene In as study long will guide XXX Indeed,
And engineering, acids XXX to or about length of bases the protein for protein amino a XXX correspond subunit.
offering. revenue synbio, we forward we As through product for believe look we growth, for look continued segment significant we opportunity enhanced in synbio the pharmaceutical a have
year, currently products and we believe add calendar in line XXXX late curve in new which our growth We several synbio are this targeting to beyond. will
XXXX, For of target of third with the we customers now these genomics in fiscal targeted enrichment XXX NGS, products XX out and customers to shipped quarter production. in more than
For grow pilot our is production. NGS, our moving base continues from through to to nicely our and customer revenue pipeline
orders expect to placing [Indiscernible] another before several through be have products that as order. we we work purchase quarters will inventory lumpy their As require and said large then previously, customers large
of opportunities. In see majority source diagnostic revenue the addition we our testing which today, a of market to growing additional of our is two companies, large base
The research first is market. the in
effectively. In mouse leveraging and custom June, generating the in introduced we our exome, cost strength rapidly panels
collected, [Indiscernible] is competitors is over While based that offering our information sequence sequence the five mouse years old. data and constantly on was exome from being for mouse
expect differentiation. includes this most consensus up-to-date exome a source we to genome Our and build the mouse of be significant
an different of effectively In our is and in addition, capabilities design offering panel and a and our custom cost large exceptional the panel in species an entirely platform. feat quickly reflects technology value
broad to we additional to line, range research specific NGS our of human product need. offer a Moving addition intend panels in forward, for species to broadening non-human
area that of beginning the The is growth in the July, micro $XXX,XXX.XX arrays conversion SNP see from to the NGS. where In second NGS. are conversion from array in to we received we orders
have mentioned have target intend Twist expensive platform we previously, we sequencing running less continue and to microarrays capture, the for this to that As can customers use be DNA demonstrated for analysis [Indiscernible] we than sequencing preparation library conversion. on using and SNP enable several
million. to market represents used extensively a and beef, are arrays used the believe space, SNP other chicken, total biotech testing array the salmon, $XXX food market opportunity genotype they that also products. While segment extensively the consumer DNA in in market SNP agricultural We are together, of
some at to substantial. area this shift the expand unique opportunity SNP platform to for the time penetrate said, to provides combination the on compared We price platform. available our our market in is as Twist sequencing for attractive workflow point long-term richer do take with an it data medium to expect arrays. it And represents genotyping NGS That to a of
During the NGS platform. our we platform their e-commerce NGS of NGS to order quarter, All are products third fiscal able can status launched now track for through and products. our customers purchase standard e-commerce our customers several select
launch quarter, implementation. for several current panel and During intend features the additional custom e-commerce we to design
Therefore, indicating our ahead existing fiscal of in at to I the the detailed provide and in in the remain these QX, on guidance meet future near-term orders remain year, revenues let at commentary. revenue we track orders costs ahead X topline as $XX. into growth businesses, Looking strongly Jim for bioengineering and revenue. million turn will
libraries. our Moving continue to GPCR on we as we -- internally Therapeutics continued validate verticals partners, to Biopharma, Pandion with our for have collaborate to LakePharma and
cells As plays we Alzheimer's. pancreatic and in promotes previously reported, have Type an which from initial role important leads functional and X Parkinson's diabetes beta against identified GLPXR, -- insulin suppression and
target, and of one itself power important of note to antibodies being in scientific the like several that functional our is to of I'd identify demonstration able platform. an against GPCR
for we relevant against am report In that of and GPCR three quarter, functionally other total last addition, I targets important to targets. identified pleased a two
forward, Going these to explore monetization. the packages are needed typical workflow leads we to order their data through build in characterization the running
pipeline to continuing targets. build to other explore also leads against We're targets multiple a of
antibody domain have are Single libraries. single series smaller antibody antibodies created fragments We than whole a are that also domain much a antibody. of
chains and of stable A characterization antibodies light whole are development. that as heavy fragments. The fragments antibodies These heavy from libraries antibodies of engineered discovery for potentially two initial are modular of and VHS composed and robust both started are called chain antibody and design two single and the also small these is as other chains, faster library. well
[Indiscernible] opportunities to Further on, libraries us screened find make to to enables functionality that and targets. difficult diverse manufacture content future rapidly be can for cost-effectively leads enabling multiple ability against with our specific us quickly such
development for capabilities. making good progress toward new collaborations tools, and are these discovery and early With we partnerships establishing
contract receive government under continuing Turning our though no to on non-dilutive storage, there the with for on remain data front, funding funding contract. a are encouraged we we progress that guarantees negotiation DNA data we will this are through this storage,
We announce our this also data forward chip storage. are we design that generation excited in anticipation to of to are next specific program, DNA the with proceeding silicon of
synthesis density. will chip part production, device a density. development chip fabricated we and execute silicon as similar key require feature would compatible driver be path CMOS designs and dramatically would continue which will engineering A our and the designed be A to design quarters increasing multiple to for roadmap to multiple with of be methodical for our
to The designs first X X phase will device be to characterize of microns.
of cost quite and as the cost oligo decrease stored of reminder, decreases, the the rapidly. size a bytes As feature
similar is designs would or tested once as instance, a cost be For to X going obtained, micron, can different chip a found by times device XX decrease smaller, XXXx. fabricated quickly. XX is and Also, the from relatively micron XX-squared reminder, which
this milestone to So, a improve. key future represents
encouraged competitive the by with cost and storage to potential long-term storage options. make Although are we progress DNA our
also consulted both we market. SanDisk. for storage to for the importantly, in flash the half he instrumental added us experience During has of our incredible was a storage last depth the Chan and Nelson and industry of year market And at in and building and the quarter, brings an Directors. of the semiconductor introducing Nelson in Board
that Imagene, supplies encoded a without Finally, as for commercial to of product. target steel in a French the a to service contract market very DNA we digital company commercial that more This data data storage signed piece DNAshells, stainless is degradation. small DNA recently with one digital capsules bring store infrastructure
our advanced strategy, of customers. in China Asian States. to from process for market, to with the technology delivery NGS we the expedite regard reiterate Finally, By the we proprietary able order a in standard products all be time I United that to keeping facility of for these more our building would will would assemble our be back-end to like the China to
facility this property products NGS be quickly. who their the In the of We be of needs with protect need initial expect shipments ready this to from customers space still and meet integral still will before will able way, our we the end XXXX. calendar our
this review the I like the time, over turn would Jim to call quarter. results to for At financial to our
